array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Novartis Gene Therapies, Inc."
["slug"]=>
string(19) "a26d9-us-avexis-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/35cea00f-69c0-468d-b166-ddd4f49dfa0c"
["description"]=>
string(639) "Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP"
["address_street"]=>
string(24) "2275 Half Day Rd Ste 200"
["address_place"]=>
string(11) "Bannockburn"
["address_region"]=>
string(8) "Illinois"
["founding_date"]=>
string(10) "2010-02-28"
["website_domain"]=>
string(12) "novartis.com"
["website_url"]=>
string(24) "https://www.novartis.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(219)
["article_count"]=>
int(7829)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(163) "Stock market ticker: Swiss stock exchange directionless before ECB interest rate decision - Analyst sees financial stocks 16 percent higher - Six new price targets"
["snippet_en"]=>
string(58) "The Swiss stock market was holding up on Thursday morning."
["url"]=>
string(182) "https://www.cash.ch/news/top-news/borsen-ticker-smi-vorborslich-hoher-givaudan-und-vat-im-mittelpunkt-inflationsdaten-vergraulen-anleger-an-der-wall-street-zwei-neue-kursziele-701298"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f5e8205d-9bf4-450d-ac68-118781d49f39"
["source"]=>
string(7) "cash.ch"
["publication_date"]=>
string(10) "2024-04-11"
["categories"]=>
array(5) {
[0]=>
string(12) "Going Public"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(18) "General Investment"
[3]=>
string(15) "Market Movement"
[4]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(100) "Largest ever UK health research programme to benefit from Novartis’ multi-million pound investment"
["snippet_en"]=>
string(214) "· Novartis supports Our Future Heath, the UK’s largest ever health research programme, with £12.5 million investment · The funding will help Our Future Heath fulfil its ambitions of enabling the..."
["url"]=>
string(148) "https://www.pharmiweb.com/press-release/2024-04-03/largest-ever-uk-health-research-programme-to-benefit-from-novartis-multi-million-pound-investment"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/05426515-dc2c-45dc-9650-529d14a80836"
["source"]=>
string(13) "pharmiweb.com"
["publication_date"]=>
string(10) "2024-04-03"
["categories"]=>
array(1) {
[0]=>
string(18) "General Investment"
}
}
[2]=>
array(7) {
["title_en"]=>
string(55) "Harnessing AI for Drug Discovery: Top 3 Stocks to Watch"
["snippet_en"]=>
string(133) "As biotech innovators look to AI to smoothen out the drug discovery process, the leaders in the scene could stand to benefit greatly."
["url"]=>
string(89) "https://investorplace.com/2024/03/harnessing-ai-for-drug-discovery-top-3-stocks-to-watch/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/79f75e4b-f590-4cf7-b9e6-67c63e7a65d2"
["source"]=>
string(17) "investorplace.com"
["publication_date"]=>
string(10) "2024-03-26"
["categories"]=>
array(2) {
[0]=>
string(12) "Slash Prices"
[1]=>
string(18) "General Investment"
}
}
[3]=>
array(7) {
["title_en"]=>
string(114) "EQS-News: MorphoSys announces US antitrust clearance of planned acquisition by Novartis under the HSR Act (German)"
["snippet_en"]=>
string(100) "BÖRSE ONLINE has been helping investors with their investment decisions week after week since 1987."
["url"]=>
string(163) "https://www.boerse-online.de/dpa-afx/eqs-news-morphosys-gibt-us-kartellfreigabe-der-geplanten-uebernahme-durch-novartis-gemaess-hsr-act-bekannt-deutsch-359248.html"
["image_url"]=>
NULL
["source"]=>
string(16) "boerse-online.de"
["publication_date"]=>
string(10) "2024-03-22"
["categories"]=>
array(3) {
[0]=>
string(11) "Acquisition"
[1]=>
string(9) "Antitrust"
[2]=>
string(18) "General Investment"
}
}
[4]=>
array(7) {
["title_en"]=>
string(85) "Boston Common Asset Management LLC Decreases Stock Holdings in Novartis AG (NYSE:NVS)"
["snippet_en"]=>
string(300) "Boston Common Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,545 shares of the company's stock after selling 13,927 shares during"
["url"]=>
string(73) "https://www.marketbeat.com/instant-alerts/nyse-nvs-sec-filing-2024-03-16/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/9d31c5fc-7289-4792-89aa-0b87981aaef2"
["source"]=>
string(14) "marketbeat.com"
["publication_date"]=>
string(10) "2024-03-16"
["categories"]=>
array(5) {
[0]=>
string(11) "Regulations"
[1]=>
string(18) "General Investment"
[2]=>
string(24) "Quarterly/Annual Figures"
[3]=>
string(12) "Stock Market"
[4]=>
string(31) "Financial Update/Profit Warning"
}
}
[5]=>
array(7) {
["title_en"]=>
string(78) "ROUNDUP: Morphosys with higher loss - takeover process by Novartis is underway"
["snippet_en"]=>
string(100) "BÖRSE ONLINE has been helping investors with their investment decisions week after week since 1987."
["url"]=>
string(127) "https://www.boerse-online.de/dpa-afx/roundup-morphosys-mit-hoeherem-verlust-uebernahmeprozess-durch-novartis-laeuft-356960.html"
["image_url"]=>
NULL
["source"]=>
string(16) "boerse-online.de"
["publication_date"]=>
string(10) "2024-03-13"
["categories"]=>
array(1) {
[0]=>
string(18) "General Investment"
}
}
[6]=>
array(7) {
["title_en"]=>
string(45) "13 Best Pharma Dividend Stocks To Buy in 2024"
["snippet_en"]=>
string(221) "In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024."
["url"]=>
string(76) "https://finance.yahoo.com/news/13-best-pharma-dividend-stocks-075655155.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/30611107-1079-4fd8-b5b6-71907fac15d1"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2024-03-05"
["categories"]=>
array(4) {
[0]=>
string(12) "Stock Market"
[1]=>
string(11) "Acquisition"
[2]=>
string(15) "Deals & Tenders"
[3]=>
string(18) "General Investment"
}
}
[7]=>
array(7) {
["title_en"]=>
string(29) "Salamanca: new Novartis plant"
["snippet_en"]=>
string(198) "The president of the Government of Castilla y León, Alfonso Fernández Mañueco, today visited the works of the new Novartis plant in Castellanos de Moriscos, Salamanca, which has had an investment"
["url"]=>
string(89) "https://salamancartvaldia.es/noticia/2024-03-01-salamanca-nueva-planta-de-novartis-341795"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c902da15-6cbc-4ea0-816b-8a4f84160389"
["source"]=>
string(20) "salamancartvaldia.es"
["publication_date"]=>
string(10) "2024-03-01"
["categories"]=>
array(8) {
[0]=>
string(12) "Staff hiring"
[1]=>
string(37) "Product Design & Lifecycle Management"
[2]=>
string(7) "Opening"
[3]=>
string(18) "General Investment"
[4]=>
string(40) "Waste and hazardous materials management"
[5]=>
string(18) "Expansion & Growth"
[6]=>
string(17) "Energy Management"
[7]=>
string(14) "Product Launch"
}
}
[8]=>
array(7) {
["title_en"]=>
string(58) "This Effective Asthma Medication May Reduce Some Allergies"
["snippet_en"]=>
string(131) "Find all the economic and stock market news, advice on investing your money, employment files and the real estate market on Capital"
["url"]=>
string(138) "https://www.capital.fr/economie-politique/ce-medicament-efficace-contre-l-asthme-pourrait-etre-efficace-contre-certaines-allergies-1492918"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a088e02a-321f-4105-917e-4378ad2fd63c"
["source"]=>
string(10) "capital.fr"
["publication_date"]=>
string(10) "2024-02-28"
["categories"]=>
array(8) {
[0]=>
string(19) "Economic Conditions"
[1]=>
string(23) "Real estate development"
[2]=>
string(18) "General Investment"
[3]=>
string(24) "Stock Research & Ratings"
[4]=>
string(15) "Market Movement"
[5]=>
string(26) "Product Quality and safety"
[6]=>
string(12) "Stock Market"
[7]=>
string(11) "Name Change"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(527)
}
[1]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(450)
}
[2]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(433)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(306)
}
[4]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(302)
}
[5]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(242)
}
[6]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(238)
}
[7]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(232)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(194)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(189)
}
[10]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(179)
}
[11]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(163)
}
[12]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(161)
}
[13]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(160)
}
[14]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(143)
}
[15]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(133)
}
[16]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(130)
}
[17]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(125)
}
[18]=>
array(2) {
["name"]=>
string(12) "Going Public"
["count"]=>
int(119)
}
[19]=>
array(2) {
["name"]=>
string(8) "spin-off"
["count"]=>
int(114)
}
[20]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(112)
}
[21]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(108)
}
[22]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(98)
}
[23]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(98)
}
[24]=>
array(2) {
["name"]=>
string(12) "Staff hiring"
["count"]=>
int(85)
}
[25]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(85)
}
[26]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(81)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(80)
}
[28]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(78)
}
[29]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(74)
}
}
}
a26d9-us-avexis-inc
Novartis Gene Therapies, Inc.
Location
Illinois
Founded
2010-02-28
Website
https://www.novartis.com
Articles
7829 Articles
Category
Pharmaceutical Preparations
Description
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.
Around 108,000 people of more than 140 nationalities work at Novartis around the world.
See our community guidelines: http://bit.ly/2JnT2CP
· Novartis supports Our Future Heath, the UK’s largest ever health research programme, with £12.5 million investment · The funding will help Our Future Heath fulfil its ambitions of enabling the...
Boston Common Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 7.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 173,545 shares of the company's stock after selling 13,927 shares during
In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024.
The president of the Government of Castilla y León, Alfonso Fernández Mañueco, today visited the works of the new Novartis plant in Castellanos de Moriscos, Salamanca, which has had an investment
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
